CD74 is dispensable for development of chronic lymphocytic leukemia in Eµ-TCL1 transgenic mice

References

• Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371:1017–1029.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16:145–162.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Fischer K, Eichhorst B, et al. Targeted Therapy of CLL. Oncol Res Treat. 2016;39:768–778.
   PubMed Web of Science ®Google Scholar
• Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma. 2011;52:1446–1454.
   PubMed Web of Science ®Google Scholar
• Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955–6960.
   PubMed Web of Science ®Google Scholar
• Reinart N, Nguyen PH, Boucas J, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood. 2013;121:812–821.
   PubMed Web of Science ®Google Scholar
• Fedorchenko O, Stiefelhagen M, Peer Zada AA, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood. 2013;121:4126–4136.
   PubMed Web of Science ®Google Scholar
• Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta. 2002;1542:1–13.
   PubMed Web of Science ®Google Scholar
• Wraight CJ, van Endert P, Moller P, et al. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem. 1990;265:5787–5792.
   PubMed Web of Science ®Google Scholar
• Fernandez N, Klidis A. Molecular profiles of the cell membrane bound and cytoplasmic forms of the human MHC class-II associated invariant polypeptides. Electrophoresis. 1991;12:523–526.
   PubMed Web of Science ®Google Scholar
• Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197:1467–1476.
   PubMed Web of Science ®Google Scholar
• Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25:595–606.
   PubMed Web of Science ®Google Scholar
• Burton JDS, Ely R, Cardillo S, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res. 2004;10:6606–6011.
   PubMed Web of Science ®Google Scholar
• Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol. 2009;15:2855–2861.
   PubMed Web of Science ®Google Scholar
• Bikoff EKH, Episkopou L, van Meerwijk V, et al. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J Exp Med. 1993;177:1699–1712.
   PubMed Web of Science ®Google Scholar
• Viville S, Neefjes J, Lotteau V, et al. Mice lacking the MHC class II-associated invariant Chain. Cell. 1993;72:635–648.
   PubMed Web of Science ®Google Scholar
• Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25:1452–1458.
   PubMed Web of Science ®Google Scholar
• Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci Usa. 2007;104:13408–13413.
   PubMed Web of Science ®Google Scholar
• Benlagha K, Park S, Guinamard R, et al. Mechanisms governing B cell developmental defects in invariant chain-deficient mice. J Immunol. 2004;172:2076–2083.
   PubMed Web of Science ®Google Scholar
• Herling M, Patel KA, Hsi ED, et al. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007;31:1123–1129.
   PubMed Web of Science ®Google Scholar
• Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.
   PubMed Web of Science ®Google Scholar
• Maehr R, Kraus M, Ploegh HL. Mice deficient in invariant-chain and MHC class II exhibit a normal mature B2 cell compartment. Eur J Immunol. 2004;34:2230–2236.
   PubMed Web of Science ®Google Scholar
• Brocks T, Fedorchenko O, Schliermann N, et al. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. Faseb J. 2017;31:526–543.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, et al. Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Starlets DG, Binsky Y, Haran I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107:4807–4816.
   PubMed Web of Science ®Google Scholar
• Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer. 2005;5:640–648.
   PubMed Web of Science ®Google Scholar
• Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20:280–285.
   PubMed Web of Science ®Google Scholar
• Ropars V, Despouy G, Stern MH, et al. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. PLoS One. 2009;4:e6567.
   PubMed Web of Science ®Google Scholar
• Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111:328–337.
   PubMed Web of Science ®Google Scholar
• Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587–596.
   PubMed Web of Science ®Google Scholar
• Schwartz V, Kruttgen A, Weis J, et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur J Cell Biol. 2012;91:435–449.
   PubMed Web of Science ®Google Scholar
• Binsky I, Lantner F, Grabovsky V, et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol. 2010;184:4761–4769.
   PubMed Web of Science ®Google Scholar
• Haran M, Mirkin V, Braester A, et al. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: a patient based approach. Br J Haematol. 2018;182:125–128.
   PubMed Web of Science ®Google Scholar